De-List from NASDAQ Europe

RNS Number:9993O
Antisoma PLC
26 August 2003


Antisoma to de-list from Nasdaq Europe because of forthcoming closure of market
            Shares to remain listed on the London Stock Exchange


26 August 2003, London, UK: Antisoma  (LSE: ASM- Nasdaq Europe: ASOM), the
UK-based biopharmaceutical company, today announces that it has received
approval for a voluntary de-listing from the Nasdaq Europe Market. The
de-listing of Antisoma shares will be effective from the close of business on
Wednesday 10 September 2003. The decision to de-list follows the announcement by
Nasdaq Europe of its intention to close by the end of November 2003.

Following the de-listing, all Antisoma shares will continue to be traded on the
London Stock Exchange, where the majority of trading takes place at present.
Existing shareholders will not have to take any action to transfer their
shareholdings. Importantly, they will not incur any additional costs as a result
of the de-listing.

Antisoma will continue to provide its shareholders with press releases and
related company information on www.antisoma.com.



Enquiries:


Antisoma plc
Raymond Spencer, Chief Financial Officer                Tel: [phone]

Financial Dynamics

Jonathan Birt                                           Tel: [phone]





About Antisoma

Based in London, UK, Antisoma is a biopharmaceutical company that develops novel
products for the treatment of cancer. The Company fills its development pipeline
by acquiring promising new product candidates from internationally recognised
academic or cancer research institutions.  Its core activity is the pre-clinical
and clinical development of these drug candidates. Antisoma forms partnerships
with pharmaceutical companies to bring its products to market.  In November
2002, Antisoma signed a ground-breaking collaboration agreement with Roche to
develop and commercialise products from Antisoma's pipeline.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCPUUQARUPWGRP